# EDGAR Filing Document

**Accession Number:** 0001958829
**File Stem:** 0001493152-23-004564
**Filing Date:** 2023-2
**Character Count:** 9074
**Document Hash:** 0e1c0bd8dd0a8f0d9bde0895c8fd0c46
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-004564.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001493152-23-004564

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZyVersa Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001859007
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 862685744
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93211
- **FILM NUMBER:** 23621763

**BUSINESS ADDRESS:**
- **STREET 1:** 217 W. MAIN STREET
- **CITY:** SOMERVILLE
- **STATE:** NJ
- **ZIP:** 08876
- **BUSINESS PHONE:** 908-370-5102

**MAIL ADDRESS:**
- **STREET 1:** 217 W. MAIN STREET
- **CITY:** SOMERVILLE
- **STATE:** NJ
- **ZIP:** 08876

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Larkspur Health Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210426
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INCON Co., Ltd.
- **CENTRAL INDEX KEY:** 0001958829
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** M5
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 4/F 16-17 LS-RO 91BEON-GIL
- **CITY:** DONGAN-GU ANYANG, GYEONGGI
- **STATE:** M5
- **ZIP:** 14042
- **BUSINESS PHONE:** 82 (31) 4558600

**MAIL ADDRESS:**
- **STREET 1:** 4/F 16-17 LS-RO 91BEON-GIL
- **CITY:** DONGAN-GU ANYANG, GYEONGGI
- **STATE:** M5
- **ZIP:** 14042

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**(Rule 13d-102)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO**

**RULE 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)**

**(Amendment No.)\***

**ZyVersa Therapeutics, Inc.**

**(Name of Issuer)**

**Common Stock**

**(Title of Class of Securities)**

**98987D102**

**(CUSIP Number)**

**December 31, 2022**

**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

| | | |
|:---|:---|:---|
| **1.** | **NAMES OF REPORTING PERSONS**<br> **I.R.S. IDENTIFICATION NUMBER OF ABOVE PERSONS (ENTITIES ONLY):**<br>INCON Co., Ltd.<br> 000000000 | **NAMES OF REPORTING PERSONS**<br> **I.R.S. IDENTIFICATION NUMBER OF ABOVE PERSONS (ENTITIES ONLY):**<br>INCON Co., Ltd.<br> 000000000 |
| **2.** | **CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** <br> (a) ☐<br> (b) ☐  | **CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** <br> (a) ☐<br> (b) ☐  |
| **3.** | **SEC USE ONLY**  | **SEC USE ONLY**  |
| **4.** | **CITIZENSHIP OR PLACE OF ORGANIZATION**<br>KOREA, REPUBLIC OF  | **CITIZENSHIP OR PLACE OF ORGANIZATION**<br>KOREA, REPUBLIC OF  |
| <br>**NUMBER OF**<br> **SHARES**<br> **BENEFICIALLY**<br> **OWNED BY EACH**<br> **REPORTING**<br> **PERSON WITH** | **5.** | **SOLE VOTING POWER**<br>1,947,901 (includes 450,702 warrants)  |
| <br>**NUMBER OF**<br> **SHARES**<br> **BENEFICIALLY**<br> **OWNED BY EACH**<br> **REPORTING**<br> **PERSON WITH** | **6.** | **SHARED VOTING POWER**<br> 0  |
| <br>**NUMBER OF**<br> **SHARES**<br> **BENEFICIALLY**<br> **OWNED BY EACH**<br> **REPORTING**<br> **PERSON WITH** | **7.** | **SOLE DISPOSITIVE POWER**<br>1,947,901 (includes 450,702 warrants)  |
| <br>**NUMBER OF**<br> **SHARES**<br> **BENEFICIALLY**<br> **OWNED BY EACH**<br> **REPORTING**<br> **PERSON WITH** | **8.** | **SHARED DISPOSITIVE POWER** <br> 0  |
| **9.** | **AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON**<br>1,947,901 (includes 450,702 warrants)  | **AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON**<br>1,947,901 (includes 450,702 warrants)  |
| **10.** | **CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES**\*  | **CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES**\*  |
| **11.** | **PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9**<br>16.49% | **PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9**<br>16.49% |
| **12.** | **TYPE OF REPORTING PERSON\***<br>CO  | **TYPE OF REPORTING PERSON\***<br>CO  |

---

---

| | | |
|:---|:---|:---|
| \*12. | **Category** | **Symbol** |
|  | Broker Dealer | BD |
|  | Bank | BK |
|  | Insurance Company | IC |
|  | Investment Company | IV |
|  | Investment Adviser | IA |
|  | Employee Benefit Plan, Pension Fund, or Endowment Fund | EP |
|  | Parent Holding Company/Control Person | HC |
|  | Savings Association | SA |
|  | Church Plan | CP |
|  | Corporation | CO |
|  | Partnership | PN |
|  | Individual | IN |
|  | Other | OO |

---

**Item 1(a).**

**Name of Issuer**

ZyVersa Therapeutics, Inc. (f/k/a Larkspur Health Acquisition Corp.)

**Item 1(b).**

**Address of Issuer's Principal Executive Offices**

2200 N. Commerce Parkway, Suite 208, Weston, Florida 33326.

**Item 2(a).**

**Name of Person Filing**

INCON Co., Ltd.

**Item 2(b).**

**Address of Principal Business Office, or, if None, Residence**

4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI, KOREA, REPUBLIC OF 14042

**Item 2(c).**

**Citizenship**

KOREA, REPUBLIC OF

**Item 2(d).**

**Title of Class of Securities**

Common Stock (par value $0.0001 per share) and Warrants

**Item 2(e).**

**CUSIP Number**

98987D102

**Item 3.**

**If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:** 

Not Applicable. This Schedule is being filed pursuant to Rule 13d-1(d).

☐ Broker or dealer registered under Section 15 of the Exchange Act;

☐ Bank as defined in Section 3(a)(6) of the Exchange Act;

☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act;

☐ Investment company registered under Section 8 of the Investment Company Act;

☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

**Item 4.**

**Ownership**

---

| | |
|:---|:---|
| a. | Amount Beneficially Owned: |
|  | 1,947,901 (includes 450,702 warrants) |

---

---

| | |
|:---|:---|
| b. | Percent of Class: |
|  | 16.49% |

---

c. Number
 of shares as to which reporting person has:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Sole Voting Power: 1,947,901(includes 450,702 warrants)

(ii) Sole voting power: 0

(iii) Sole
dispositive power: 1,947,901 (includes 450,702 warrants)

(iv) Shared
dispositive power: 0

**Item 5.**

**Ownership of Five Percent or Less of a Class**

Not Applicable

**Item 6.**

**Ownership of More Than Five Percent on Behalf of Another Person**

Not Applicable

**Item 7.**

**Identification and Clarification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company**

Not Applicable

**Item 8.**

**Identification and Classification of Members of the Group**

Not Applicable

**Item 9.**

**Notice of Dissolution of Group**

Not Applicable

**Item 10.**

**Certification**

This Schedule is being filed pursuant to 13d-1(d).

By signing below we certify that, to the best of our knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose of effect.

**SIGNATURE**

After reasonable inquiry and to the best of the undersigned's knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

---

| | |
|:---|:---|
| **<u>February 14, 2023</u>** | **<u>February 14, 2023</u>** |
| **(DATE)** | **(DATE)** |
| **INCON Co., Ltd.** | **INCON Co., Ltd.** |
| By: | */s/ Seung Ku Jeon* |
| Name: | Seung Ku Jeon |
| Title: | Chief Financial Officer |
| */s/ Seung Ku Jeon* | */s/ Seung Ku Jeon* |
| **Seung Ku Jeon** | **Seung Ku Jeon** |

---